Deutsch English Français

Contact

EP2273985

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2273985

EP2273985 - CAPSULE FOR THE PREVENTION OF CARDIOVASCULAR DISEASES [Right-click to bookmark this link]
Status	Opposition rejected Status updated on 03.08.2018 Database last updated on 13.07.2024
Former	The patent has been granted Status updated on 19.04.2018
Most recent event Tooltip	03.08.2018	Opposition rejected	published on 05.09.2018 [2018/36]
Applicant(s)	For all designated states Ferrer Internacional, S.A. Gran Via Carlos III, 94 08028 Barcelona / ES
	For all designated states CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III C/Melchor Fernández Almagro, 3 28029 Madrid / ES
	[2015/38]
Former [2013/16]	For all designated states Ferrer Internacional, S.A. Gran Via Carlos III, 94 08028 Barcelona / ES
	For all designated states CNIC, Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III Melchor Fernandez Almagro, 3 28029 Madrid / ES
Former [2011/03]	For all designated states Ferrer Internacional, S.A. Gran Via Carles III 94 08028 Barcelona / ES
	For all designated states CNIC, Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III Melchor Fernandez Almagro, 3 28029 Madrid / ES
Inventor(s)	01 / GUERRERO, Marta Travessera de Dalt 73 E-08024 Barelona / ES
	02 / ORRIOLS, Anna Tortonyes 25-C 2°2a E-08242 Manresa / ES
	03 / MARTÍN, Pablo Joan XXIII 44 Bjos. 1a E-08173 Barcelona / ES
	04 / RAGA, Manuel Sors 17-21 E-08024 Barcelona / ES
	[2011/03]
Representative(s)	Reitstötter Kinzebach Patentanwälte Sternwartstraße 4 81679 München / DE
	[N/P]
Former [2016/07]	Reitstötter Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
Former [2011/03]	Reitstötter - Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
Application number, filing date	09724677.1	25.03.2009
	[2011/03]
	WO2009EP53545
Priority number, date	EP20080153615	28.03.2008 Original published format: EP 08153615
	[2011/03]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2009118359
	Date:	01.10.2009
	Language:	EN
	[2009/40]
	Type:	A2 Application without search report
	No.:	EP2273985
	Date:	19.01.2011
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 01.10.2009 takes the place of the publication of the European patent application.
	[2011/03]
	Type:	B1 Patent specification
	No.:	EP2273985
	Date:	17.02.2016
	Language:	EN
	[2016/07]
Search report(s)	International search report - published on:	EP	06.05.2010
Classification	IPC:	A61K31/60, A61K31/22, A61K31/366, A61K31/401, A61K31/403, A61K31/405, A61K31/616, A61K9/48, A61K9/20, A61K9/28, A61P9/00	[2015/38]
	CPC:	A61K9/4816 (EP,US); A61K31/366 (EP,US); A61K31/403 (EP,US); A61K31/60 (EP,US); A61K31/616 (EP,US); A61K9/2009 (EP,US); (+) A61K9/2018 (EP,US); A61K9/2054 (EP,US); A61K9/2059 (EP,US); A61K9/284 (EP,US); A61K9/2866 (EP,US); A61P13/12 (EP); A61P29/00 (EP); A61P3/06 (EP); A61P3/10 (EP); A61P43/00 (EP); A61P9/00 (EP); A61P9/04 (EP); A61P9/10 (EP); A61P9/12 (EP) (-)
	C-Set:	A61K31/366, A61K2300/00 (EP,US); A61K31/403, A61K2300/00 (US,EP); A61K31/60, A61K2300/00 (US,EP); A61K31/616, A61K2300/00 (US,EP)
	Former IPC [2011/03]	A61K9/48, A61P9/00, A61K31/60, A61K31/22, A61K31/366, A61K31/401, A61K31/403, A61K31/405
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2016/07]
Former [2011/03]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR
Title	German:	KAPSEL ZUR PRÄVENTION VON KARDIOVASKULÄREN ERKRANKUNGEN	[2015/38]
	English:	CAPSULE FOR THE PREVENTION OF CARDIOVASCULAR DISEASES	[2011/03]
	French:	CAPSULE POUR LA PRÉVENTION DES MALADIES CARDIOVASCULAIRES	[2015/38]
	Former [2011/03]	KAPSEL ZUR PRÄVENTION VON HERZ-KREISLAUF-ERKRANKUNGEN
	Former [2011/03]	Capsule pour la prévention des maladies cardiovasculaires
Entry into regional phase	26.10.2010	National basic fee paid
	26.10.2010	Designation fee(s) paid
	26.10.2010	Examination fee paid
Examination procedure	02.06.2010	Request for preliminary examination filed International Preliminary Examining Authority: EP
	26.10.2010	Examination requested [2011/03]
	30.12.2010	Amendment by applicant (claims and/or description)
	22.03.2012	Despatch of a communication from the examining division (Time limit: M07)
	14.12.2012	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	15.02.2013	Reply to a communication from the examining division
	20.08.2015	Communication of intention to grant the patent
	11.12.2015	Fee for grant paid
	11.12.2015	Fee for publishing/printing paid
	11.12.2015	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 22.03.2012
Opposition(s)	Opponent(s)	01 17.11.2016 23.11.2016 ADMISSIBLE ELLIS IP LTD 53/4 George Street Edinburgh EH2 2HT / GB Opponent's representative Ellis, Michael James Ellis IP Ltd 53/4 George Street Edinburgh EH2 2HT / GB
		[2017/06]
	Former [2016/52]
	Opponent(s)	01 17.11.2016 23.11.2016 ADMISSIBLE ELLIS IP LTD Newbyth House East Linton East Lothian EH40 3DU / GB Opponent's representative Ellis, Michael James Ellis IP Ltd Newbyth House East Linton East Lothian EH40 3DU / GB
	04.01.2017	Invitation to proprietor to file observations on the notice of opposition
	15.05.2017	Reply of patent proprietor to notice(s) of opposition
	27.03.2018	Legal effect of rejection of opposition [2018/36]
	27.03.2018	Date of oral proceedings
	20.04.2018	Despatch of minutes of oral proceedings
	20.04.2018	Date of despatch of rejection of opposition
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	15.02.2013	Request for further processing filed
	15.02.2013	Full payment received (date of receipt of payment) Request granted
	04.03.2013	Decision despatched
Fees paid	Renewal fee
	31.03.2011	Renewal fee patent year 03
	30.03.2012	Renewal fee patent year 04
	27.03.2013	Renewal fee patent year 05
	27.03.2014	Renewal fee patent year 06
	27.03.2015	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	EE	17.02.2016
	IS	17.02.2016
	LT	17.02.2016
	LV	17.02.2016
	MC	17.02.2016
	MK	17.02.2016
	LU	25.03.2016
	[2018/30]
Former [2016/49]	EE	17.02.2016
	LT	17.02.2016
	LV	17.02.2016
Former [2016/39]	LT	17.02.2016
	LV	17.02.2016
Former [2016/36]	LT	17.02.2016
Cited in	International search	[A]WO0158429 (BPSI HOLDINGS INC [US], et al) [A] 1-8 * page 10, lines 7-12 *;
		[XD]WO03020243 (LONGWOOD PHARMACEUTICAL RES IN [US]) [XD] 1-8 * examples 5,6; claims 1-31 *;
		[XD]WO2004080488 (BAYER HEALTHCARE AG [DE], et al) [XD] 1-8 * examples 18,19; claims 1-19 *;
		[XD]WO2005011586 (REDDYS LAB INC DR [US], et al) [XD] 1-8 * example 5; claims 1-24 *;
		[A]EP1657265 (SHIONOGI & CO [JP], et al) [A] 1-8* figure 5; example 3 *;
		[A]US2007009591 (TRIVEDI JAY S [US], et al) [A] 1-8 * the whole document *;
		[XD]US2007116756 (KOMIREDDI PRAKASH R [IN], et al) [XD] 1-8 * examples 1,7; claims 1-17 *;
		[A]US2007166375 (PATEL SHASHANK BABABHAI [IN], et al) [A] 1-8 * example 4 *;
		[AP]WO2009022821 (HANALL PHARMACEUTICAL CO LTD [KR], et al) [AP] 1-8 * example 33; tables 8-9 *
	Examination	- LAW M R ET AL, "Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials", BMJ. BRITISH MEDICAL JOURNAL, LONDON, GB, vol. 326, no. 7404, doi:10.1136/BMJ.326.7404.1427, ISSN 0959-8146, (20030628), pages 1427 - 1431, (20030625), XP008145737 DOI: http://dx.doi.org/10.1136/bmj.326.7404.1427
		- SCHIEFFER B ET AL, "Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA, US, (20030619), vol. 91, no. 12A, ISSN 0002-9149, pages 12H - 18H, XP001573308 DOI: http://dx.doi.org/10.1016/S0002-9149(03)00429-6
		- HOLZGRABE U, "How stable are drugs Wie stabil sind Anneimittel", PHARMAZEUTISCHE ZEITUNG, GOVI VERLAG, ESCHBORN, DE, (20040101), vol. 149, no. 26, ISSN 0031-7136, pages 32 - 35, XP008145787
		- FEHER GERGELY ET AL, "Aspirin Resistance: Possible Roles of Cardiovascular Risk Factors, Previous Disease History, Concomitant Medications and Haemorrheological Variables", DRUGS & AGING, ADIS INTERNATIONAL LTD, AUCKLAND,NEW ZEALAND, (20060101), vol. 23, no. 7, ISSN 1170-229X, pages 559 - 567, XP008145786
	Opposition	US5442008
		WO03020243
		WO2009022821
		- FEGELY K et al., "Correlation of free salicylic acid content to the water vapor transmission properties of aqueous film coating systems", Poster presentation, American Association of Pharmaceutical Scientists Annual Meeting, Salt Lake City, UT, USA, (20031001), pages 1 - 6, URL: https://www.colorcon.com/literature/marketing/fc/Opadry%20amb/ads_opadry_amb_corr_free_salic_acid.pdf, XP055323873
		- Anonymous, "Opadry® AMB, Colorcon", Colorcon, (20030321), page 1, URL: http://www.fdec.com.tw/static/media/uploads/documents/opadry_amb-1.pdf, XP055325666
		- Sven Stegemann, "Hard gelatin capsules today - and tomorrow", Capsugel Library, (20020000), pages 2 - 23, URL: http://www.capsugel.com/media/library/hard-gelatin-capsules-today-and-tomorrow.pdf, XP008128828
		- DAVID B. TROY et al., "Chapter 45: Oral solid dosage forms", Remington The Science and Practice of Pharmacy 21st edition, page 919, ISBN 0-7817-4673-6, XP055323937
		- Clark A Kelly, "Determination of the decomposition of aspirin", J Pharm Sci., (19700800), vol. 59, no. 8, pages 1053 - 1079, XP008182502 DOI: http://dx.doi.org/10.1002/jps.2600590802
		- Anonymous, "ICH HARMONISED TRIPARTITE GUIDELINE, 2003 STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS Q1A(R2", INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE,, (20030206), pages 1 - 24, URL: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf, XP055325580
		- T L Rogers, "Hypromellose", T L Rogers, RAYMOND C. ROWE, Handbook of Pharmaceutical Excipients, Pharmaceutical Press, (20090220), pages 326 - 329, ISBN 9780853697923, XP055325597
		- N J Wald, M R Law, "A strategy to reduce cardiovascular disease by more than 80%", BMJ. BRITISH MEDICAL JOURNAL, (20030628), vol. 326, pages 1 - 6, XP008042512
		- Anonymous, "Simvacor. Summary of product characteristics.", (20050401), pages 1 - 12, URL: http://www.actavis.com.mt/NR/rdonlyres/3231D4F1-BEAF-434A-B273-AF6B7F40554F/0/Si.., XP055325622

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p